CKS1B and ovarian carcinoma: Then, there was no significant correlation discovered between CKS1B expression of traditional high-throughput data and clinical traits comprised of drug sensitivity, recurrence, metastasis, and prognosis of OS patients, which is contrary with studies demonstrating that upregulated CKS1B mRNA expression is a risk factor bringing about the resistance of tumor cells for chemotherapy and poor prognosis in tumors including colorectal carcinoma, gastric carcinoma, follicular lymphoma, and ovarian carcinoma [68–71].